Overview of Telfast D

Quick Facts

Property	Description
Active Ingredients	Fexofenadine Hydrochloride and Pseudoephedrine Hydrochloride
Form	Extended-release tablet (Modified-release)
Pharmacological Class	Antihistamine-decongestant combination
Common Use	Symptomatic relief of upper respiratory symptoms/allergic rhinitis
Origin	Synthetic/Derived

What Type of Medicine is Telfast D and How is it Classified?

Telfast D is defined as a fixed-dose combination product belonging to the antihistamine-decongestant combination pharmacological class. It is a dual-action oral medication composed of two distinct synthetic compounds. This classification is clinically recognized for providing combined therapeutic effects, unlike treatments that offer only single-ingredient antihistamines.

The drug's official classification reflects its dual-action formula, a key differentiating feature. As an oral medication, it ensures that the active compounds are systematically distributed, acting on areas of allergic inflammation and swelling throughout the upper respiratory tract. Similar combination products that share this formulation include the analogue brand Allegra-D, which shares the same active ingredients.

What Active Ingredients Does Telfast D Contain?

Telfast D contains two distinct active ingredients: the second-generation H1-receptor antagonist, Fexofenadine Hydrochloride, and the systemic sympathomimetic amine, Pseudoephedrine Hydrochloride. These two synthesized compounds are presented in an extended-release tablet form, which controls the dissolution and absorption rates. The formulation combines the non-sedating profile of Fexofenadine with the decongestant effect of Pseudoephedrine, allowing for the simultaneous management of common allergy symptoms and nasal blockage.

The design of the extended-release matrix ensures that the therapeutic effects of both the antihistamine and the decongestant are sustained over a prolonged period. Fexofenadine is recognized for its non-sedating profile, acting peripherally to suppress the allergic response, while Pseudoephedrine functions as an alpha-adrenergic agonist, causing vasoconstriction that shrinks swollen mucous membranes.

What is the General Therapeutic Purpose of the Dual-Action Formula?

The primary therapeutic purpose of the Telfast D dual-action formula is to provide sustained symptomatic relief for discomforts associated with seasonal allergic rhinitis and related upper respiratory tract symptoms. This combination is designed to relieve both nasal congestion and other seasonal allergic rhinitis symptoms, providing a comprehensive approach to managing these conditions.

The core benefit is the synchronized, broad-spectrum action: the Fexofenadine component alleviates symptoms such as sneezing, itching, and watery eyes, while the Pseudoephedrine component actively reduces nasal swelling and congestion. This combination, delivered in a modified-release tablet, offers a more complete intervention than a single-ingredient product, making it useful for individuals whose allergic reactions include significant nasal blockages.

What side effects are possible with Telfast D?

Official Adverse Reactions and Safety Profile

The safety profile of Telfast D is documented based on the clinical trial and post-marketing data for the fexofenadine and pseudoephedrine combination, categorized by frequency and the body's organ systems.

Frequency-Classified Adverse Reactions

The official labeling classifies certain reactions by how often they occurred:

Frequency	Examples of Adverse Reaction
Common	Headache, Drowsiness, Dizziness, Nausea
Uncommon	Fatigue
Not Known	Insomnia, Nervousness, Tachycardia, Hypersensitivity reactions

Adverse reactions associated with the Not Known frequency category are based on post-marketing reports where the frequency cannot be reliably estimated.

System-Organ Classes and Serious Events

Adverse effects are documented across several body systems, including Nervous System Disorders, Gastrointestinal Disorders, Psychiatric Disorders, and Cardiac Disorders.

Serious adverse reactions listed in regulatory documents include manifestations of Systemic Hypersensitivity Reactions (such as angioedema or anaphylaxis) and potential Cardiovascular Events (such as stroke, seizures, or severe hypertension) primarily linked to the pseudoephedrine component.

Population-Specific Constraints and Restrictions

Regulatory safety statements impose specific limits on use:

Contraindications: The medicine is not to be used by individuals with severe high blood pressure, severe coronary artery disease, narrow-angle glaucoma, or urinary retention.
Caution: Use requires particular caution in patients with diabetes mellitus, hyperthyroidism, and ischemic heart disease.
Special Populations: The combination is not recommended for children under 12 years. Patients who are older adults or who have renal or hepatic impairment should consult a healthcare professional before use.

Overdose and Emergency Response

Overdose and When to Seek Help

This information is based on official regulatory prescribing documents for fexofenadine hydrochloride and pseudoephedrine hydrochloride (Telfast D).

Documented Overdose Manifestations

Symptoms of overdose are typically an exaggeration of known side effects. Overdose of the fexofenadine component may present as dizziness, drowsiness (somnolence), and dry mouth. Due to the pseudoephedrine component, overdose can lead to more severe outcomes, including irregular heartbeat, convulsions or seizures, and the possibility of cardiovascular collapse.

Immediate Actions and Management

If an overdose is suspected, seek medical help immediately or contact a Poison Control Center right away.

Immediate emergency services (e.g., 911) are required if the affected person has collapsed, had a seizure, has trouble breathing, or cannot be awakened.

Management generally involves symptomatic and supportive treatment, including standard measures to remove any unabsorbed drug from the body. Regulatory information indicates that hemodialysis is not an effective method for removing fexofenadine from the bloodstream.

Population-Specific Considerations

Patients with decreased renal function (kidney impairment) have an increased risk of accumulation of both drug components due to a prolonged half-life, which necessitates caution and may require a dosage adjustment.

Therapeutic Uses of Telfast D

What Telfast D treats: main uses and benefits

Telfast D is a medicine applied across domains where additional symptomatic support is needed for conditions involving episodic or fluctuating manifestations, such as seasonal or perennial allergic rhinitis. This approach is commonly used to help with symptom clusters that may become intense or disruptive due to allergies. The medicine is applied in scenarios where additional management of discomfort is required.

Core Therapeutic Domains

The medicine is relevant for managing symptoms that interfere with daily comfort. It provides supportive relief for common indications including sneezing, runny nose, itchy throat, and itchy eyes. It also assists with maintaining functional stability by easing symptoms related to heightened physiological activity like nasal congestion and sinus pressure.

Telfast D is commonly used to help with symptom clusters that play a role in managing symptoms that create noticeable physiological strain. This support helps ease the overall symptom burden, particularly during periods of heightened symptoms associated with acute or episodic changes. The supportive relief helps patients cope more steadily with symptom fluctuations.

Quick Fact: Relief for Runny Nose and Sinus Pressure

Regulatory References

DailyMed official label

Eligibility and Restrictions for Use

The eligibility for using Telfast D, a combination product, is strictly defined by regulatory documents based on patient age and existing health status.

Contraindicated Populations

Use of this medicine is absolutely contraindicated (prohibited) for patients with a known hypersensitivity to the active ingredients or who are currently taking a Monoamine Oxidase Inhibitor (MAOI) or have stopped MAOI therapy within the last 14 days. Absolute prohibition also applies to patients with severe hypertension, severe coronary artery disease, narrow-angle glaucoma, urinary retention, and hyperthyroidism.

Age-Related Eligibility

The medicine is approved for adults and adolescents aged 12 years and older. It is not recommended for use in children under 12 years of age. Older adults (65 and over) are advised to consult a health professional due to the increased likelihood of age-related decreased renal function.

Conditional Use and Restrictions

Use is restricted in individuals with renal impairment (kidney disease) due to slower drug clearance, and the 24-hour formulation is generally not recommended in this population. Caution is also advised for patients with diabetes mellitus, non-severe hypertension, or other heart conditions. The medicine is generally not recommended for use during pregnancy or lactation (breastfeeding), as both active ingredients are excreted into breast milk.

What should I know about interactions with other medicines?

The official regulatory profile for this medicine is characterized by specific pharmacokinetic and pharmacodynamic interactions requiring administration constraints. Formal regulatory prohibitions mandate that the medicine is contraindicated for co-administration with Monoamine Oxidase Inhibitors (MAOIs), and this restriction applies for 14 days after discontinuation of MAOI therapy, due to the risk of severe hypertensive crisis. The combination is also strictly prohibited with Ergot Derivatives (such as ergotamine and dihydroergotamine) because of documented additive vasoconstrictive effects that may significantly increase blood pressure.

Clinically significant pharmacokinetic interactions occur with Oral Ketoconazole and Erythromycin, as co-administration is documented to significantly increase the systemic plasma exposure (AUC and Cmax) of Fexofenadine. Conversely, concurrent administration of Aluminum- and Magnesium-containing Antacids reduces Fexofenadine absorption, necessitating a minimum separation of 2 hours between doses as specified on the label. Pharmacodynamic interactions involve other Sympathomimetic Agents, which may result in additive cardiovascular effects. Additionally, combining with certain Antihypertensive Drugs may reduce the efficacy of the antihypertensive agent. Specific Fruit Juices (grapefruit, apple, orange) are documented to reduce Fexofenadine bioavailability via intestinal transporter inhibition, and should be avoided to maintain optimal exposure. An interaction-related constraint exists for patients with decreased renal function, who exhibit reduced clearance of both active ingredients and a risk of drug accumulation.

Mechanism of Action

How Telfast D Works — Mechanism of Action

The dual-action mechanism results from synchronized pharmacodynamic effects on two distinct physiological systems: the histamine-mediated inflammatory cascade and the autonomic vascular control system. The component Fexofenadine functions as a competitive antagonist at the peripheral Histamine H1 receptors. By occupying these receptors, the mechanism interrupts the signaling cascade initiated by endogenous histamine, thereby restricting the downstream physiological effects, including elevated vascular permeability and sensory neuron activation. Fexofenadine's mechanism is further constrained to the periphery by the P-glycoprotein efflux pump, actively restricting access to central H1 receptors.

The second component, Pseudoephedrine, acts as a sympathomimetic amine by engaging alpha-adrenergic receptors on vascular smooth muscle. This engagement is achieved through both direct agonism and the release of stored norepinephrine. The resulting physiological effect is intense vasoconstriction of arterioles and venules in the nasal mucosa. This constriction reduces the volume of pooled blood in the tissue, which leads to a reduction in the volume of the mucosal tissue (edema). The combined, sustained action of the two mechanisms results in synchronized modulation of both the chemical inflammation and the subsequent vascular response.

Dosage and Administration Information

How to Use Telfast D: Official Administration Guidelines

This section explains the general principles for the administration of the Fexofenadine HCl 180 mg / Pseudoephedrine HCl 240 mg extended-release combination product.

Administration Scope

Instruction	Detail
Route of administration	Oral administration.
Standard Dosing Schedule	One extended-release tablet (180 mg / 240 mg strength) once daily. The maximum recommended dose is one tablet per 24 hours.
Timing in relation to meals	Must be taken on an empty stomach.
Required liquid	Must be taken with water only. Fruit juices, such as grapefruit, apple, or orange, must be avoided to prevent interference with drug absorption.
Age-group rules	Approved for use in patients 12 years of age and older.

Procedural and Integrity Constraints

The dual-action tablet is designed for 24-hour modified release, necessitating specific procedural conditions during intake. The tablet must be swallowed whole and must not be crushed, broken, chewed, or divided. Altering the tablet's integrity disrupts the controlled-release mechanism of both active compounds, which is crucial for the intended dosing frequency and sustained effect. Patients with decreased renal function (kidney impairment) require a starting dose adjustment due to altered clearance rates of fexofenadine and pseudoephedrine.

The official instructions collectively define a single, standardized oral regimen that is based on the specific delivery system, ensuring correct dosage, frequency, and absorption profile.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Telfast D

Evidence for Symptomatic Relief of Seasonal Allergic Rhinitis

Research has explored whether the combination was associated with changes in symptoms in people experiencing seasonal allergic rhinitis (SAR). Studies conducted during periods of increased symptom activity have primarily used short-term, randomized controlled trials (RCTs) on populations of adults and adolescents (ages 12 and older). Research examined outcomes related to physical discomfort, such as sneezing, a runny nose, and itching, using patient-reported outcomes to evaluate episodic symptom patterns. Studies monitored data patterns related to the evolution of these common allergy symptoms over the course of the short treatment period.

Evidence for Nasal Congestion and Obstruction

The research for this medication has also specifically evaluated outcomes linked to inflammatory states, focusing heavily on nasal congestion and obstruction. This area of research involved RCTs and specialized single-dose studies where researchers used tools to take objective measurements of nasal airflow, in addition to patient-reported scores. Studies monitored data patterns related to the evolution of nasal symptoms and the association of the decongestant component with outcomes when examined in research contexts. A key limitation is that comparative evidence is lacking against a wide range of other treatments for nasal congestion.

Long-Term Studies and Follow-Up Duration

The evidence base primarily consists of efficacy trials where follow-up durations were limited, typically focusing on short-term patterns over periods of two weeks. Studies explored symptom changes with observations tracked over the 12-hour dosing intervals. Consequently, there is limited information for long-term outcomes, meaning the long-term effects are not fully established.

Evidence in Specific Patient Populations

Research has explored the medication in specific demographic groups, beyond the general adult population. Pharmacokinetic studies monitored physiological differences in how the medicine is processed in the body of adolescents and older subjects (over 65 years old). Studies have also explored patterns related to individuals with kidney impairment; data show patterns related to how the body clears the components of the drug in this subgroup, and evidence for these groups remains limited.

What Is Still Uncertain About Telfast D

The main research limitations include that results apply only to the populations studied. Data for certain groups remain insufficient, particularly regarding long-term outcomes. Subgroup findings are uncertain for several populations, such as pregnant women, as research is limited.

Key Studies & References DailyMed Label for Fexofenadine and Pseudoephedrine Extended Release Tablets (Allegra-D 24 Hour)

Frequently Asked Questions (FAQ)

Common questions about Telfast D (FAQ)

Q: How quickly should I expect Telfast D to start working?

A: Official clinical information indicates that the antihistamine component, fexofenadine, begins to take effect approximately 2 hours after administration. Since Telfast D is an extended-release medicine, the effects of both the antihistamine and the decongestant are designed to be sustained over a longer period.

Q: Can Telfast D be used to treat a common cold?

A: Official regulatory documents specify that this medicine is approved for the symptomatic relief of seasonal allergic rhinitis, commonly known as hay fever, and related upper respiratory allergies. The official documentation indicates its use is specified for seasonal allergic rhinitis, and not the common cold.

Q: Can Telfast D cause anxiety or jittery feelings?

A: The pseudoephedrine component is a sympathomimetic amine. The official safety profile includes nervousness and tachycardia (rapid heartbeat) as adverse reactions. These effects are consistent with the known stimulating properties of the pseudoephedrine component.

Q: Will Telfast D make it hard for me to sleep?

A: The medicine contains pseudoephedrine, and official post-marketing reports have included insomnia (difficulty sleeping) as a possible adverse reaction. The potential for insomnia is linked to the pseudoephedrine component's stimulant effects.

Q: Is it true that Telfast D is a combination medicine?

A: Yes, official classification defines Telfast D as a fixed-dose combination product containing two distinct active ingredients: the antihistamine fexofenadine hydrochloride and the decongestant pseudoephedrine hydrochloride.

Q: Does Telfast D interact with caffeine?

A: The pseudoephedrine component is a sympathomimetic agent. The official product information advises caution regarding its use with other stimulants, as combining them may cause additive cardiovascular effects.

Q: What are the known interactions between Telfast D and fruit juices?

A: Official instructions advise avoiding the use of certain fruit juices, specifically grapefruit, apple, and orange. These juices are documented to reduce the body’s ability to absorb and utilize the fexofenadine component.

Q: Is Telfast D used primarily for temporary or short-term symptoms?

A: The body of clinical evidence for this medicine is primarily based on short-term clinical trials, typically lasting up to two weeks in duration. These studies monitored changes in acute, episodic allergy symptoms.

Q: Can Telfast D affect blood pressure readings?

A: The pseudoephedrine component is a sympathomimetic agent that can cause or contribute to increased blood pressure. Use of the medicine is contraindicated in patients with severe hypertension.

Q: Is there a non-drowsy version of Telfast D?

A: While the antihistamine component (fexofenadine) is widely recognized as non-sedating, the official safety profile lists drowsiness as a common side effect for the combination product.

Q: Is it common to feel a racing heart after taking Telfast D?

A: The pseudoephedrine component can have stimulating effects. Official post-marketing reports have included tachycardia (rapid heartbeat), which is consistent with the side effect of tachycardia.

Q: Can Telfast D be used for year-round allergies (perennial allergies)?

A: The official therapeutic purpose is specified as the relief of symptoms associated with seasonal allergic rhinitis. The evidence base for perennial (year-round) allergies is not defined in the labeling.

Q: Is there a generic version of Telfast D available?

A: The active ingredients in Telfast D, fexofenadine hydrochloride and pseudoephedrine hydrochloride, are available in generic combination products from various manufacturers.

Q: Can I take Telfast D if I am taking an antidepressant medication?

A: Official regulatory constraints specify that the medicine is absolutely contraindicated (prohibited) for use with Monoamine Oxidase Inhibitors (MAOIs) or within 14 days of stopping MAOI therapy.

Q: What happens if I miss a dose of Telfast D?

A: The instruction provided in patient information is to take a missed dose when remembered. However, if it is almost time for the next scheduled dose, the advice is to skip the missed dose and not take double or extra doses.

Q: Can Telfast D be used to clear up sinus pressure?

A: The pseudoephedrine component is intended to reduce nasal swelling and congestion by constricting blood vessels. The medicine has been studied for its association with outcomes related to nasal obstruction.

Q: Are there any long-term side effects associated with Telfast D use?

A: Official research acknowledges there is limited information available on long-term outcomes for this combination. Efficacy trials typically focused on short-term patterns over periods of up to two weeks.

Q: Can I drive or operate machinery after taking Telfast D?

A: Patient information advises caution regarding driving or operating machinery. Patient information emphasizes the need for caution until a person is aware of how the medicine specifically affects them.

Q: Is Telfast D studied in pediatric patients?

A: The medicine is officially approved for use in adolescents 12 years of age and older. It is not recommended for use in children under 12 years.

Q: Why does the label warn against taking Telfast D close to bedtime?

A: The active decongestant, pseudoephedrine, is a stimulant (sympathomimetic amine) that can cause stimulating effects. It is associated with adverse reactions like insomnia and nervousness, particularly when taken close to the time of sleep.

Q: Is Telfast D a narcotic or addictive substance?

A: The medicine is classified as an antihistamine-decongestant combination. It is not listed as a narcotic or controlled substance under regulatory scheduling.

Q: Why might a doctor prescribe Telfast D over a single-ingredient allergy medicine?

A: The formula provides a dual-action benefit, combining an antihistamine (fexofenadine) to treat general allergy symptoms with a decongestant (pseudoephedrine) to actively reduce nasal swelling and congestion.

Q: Can Telfast D be taken if I am consuming alcohol?

A: Regulatory information for the antihistamine component (fexofenadine) indicates that no significant interaction is evidenced with concomitant alcohol consumption.

Q: What should I do if I accidentally take two tablets of Telfast D at once?

A: Regulatory patient information states the constraint of not taking double or extra doses of the medicine. In the event of a suspected overdose, regulatory guidance indicates that symptomatic and supportive treatment should be considered.

Q: Can Telfast D cause changes in blood sugar levels?

A: The pseudoephedrine component is a sympathomimetic agent that may cause increases in blood glucose concentrations. Caution is therefore advised for patients with diabetes mellitus.

Q: Why do some people feel restless or nervous after taking Telfast D?

A: The pseudoephedrine component acts as a sympathomimetic amine, which is associated with stimulant-like effects. This mechanism of action can lead to adverse reactions such as nervousness and restlessness.

Q: Does Telfast D contain gluten or common allergens?

A: The official ingredient list includes inactive excipients such as anhydrous lactose, lactose monohydrate, and corn starch. Patients with specific allergies should check the full inactive ingredient list provided by the manufacturer.

Q: Does taking Telfast D require any specific monitoring from a doctor?

A: Closer monitoring of certain health factors may be appropriate for some patients. This includes monitoring blood pressure and blood glucose levels in individuals with pre-existing conditions like hypertension or diabetes mellitus.

Q: Can people with liver impairment take Telfast D?

A: Due to limitations in data for this patient subgroup, use of the medicine by individuals with hepatic (liver) impairment requires guidance from a healthcare professional.

How should Telfast D be stored and disposed of?

How to Store and Dispose of Telfast D

Official regulatory information requires that Telfast D (fexofenadine and pseudoephedrine) be stored under specific conditions to maintain stability and safety.

Storage Requirements

Condition	Requirement
Temperature	Store at controlled room temperature.
Protection	Keep away from excess heat and excess moisture.
Packaging	Keep the medication in the container it came in and ensure the container is tightly closed.
Safety	Store out of the sight and reach of children.

Disposal Requirements

Unused or expired Telfast D must be disposed of properly according to official guidelines.

Do not dispose of the medication into a sewer, on the ground, or into any body of water.
The medication must be disposed of via an approved waste disposal plant or a designated drug take-back program.

Telfast D